poisar

Stocks · News reference

VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery

BenzingaJul 27, 2026, 11:07 AMBenzinga Newsdesk

VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222,

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 27, 2026, 11:07 AM
Checked
Jul 27, 2026, 11:07 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading